Compare EPM & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | MBIO |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.2M | 4.7M |
| IPO Year | 1996 | N/A |
| Metric | EPM | MBIO |
|---|---|---|
| Price | $4.33 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.93 | N/A |
| AVG Volume (30 Days) | 311.2K | ★ 432.3K |
| Earning Date | 02-10-2026 | 03-27-2026 |
| Dividend Yield | ★ 11.62% | N/A |
| EPS Growth | ★ 86.75 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $85,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.22 | N/A |
| P/E Ratio | $52.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.19 | $0.53 |
| 52 Week High | $5.70 | $7.00 |
| Indicator | EPM | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 46.13 |
| Support Level | $3.95 | $0.53 |
| Resistance Level | $4.25 | $1.10 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.99 | 72.97 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.